Belviq, the best-selling weight-loss drug in the United States, will be removed from Novartis or cut 400 jobs

As of 24:00 on February 13, 63851 cases had been confirmed in total; the Central Government: promoting the deep intervention of traditional Chinese medicine; Jinyintan hospital implored the convalescent to donate plasma; Novartis planned to close a British factory or cut 400 jobs; the FDA required the health material to automatically withdraw belviq As of 24:00 on February 13, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 55748 confirmed cases (10204 severe cases), 6723 cured and discharged cases (269 cases reduced in Hubei Province) and 1380 dead cases (due to repeated statistics in Hubei Province), There were 108 cases of karyocytopenia, 63851 cases of confirmed cases (1043 cases of karyocytopenia in Hubei Province) and 10109 suspected cases There were 493067 close contacts and 177984 close contacts still under medical observation (official website of National Health Commission) The central novel coronavirus pneumonia epidemic prevention working group meeting held in February 13th called for strengthening the integration of Chinese and Western medicine, promoting the whole process of deep intervention and timely promotion of effective prescriptions and proprietary Chinese medicines In order to accelerate the clinical trials of drugs, we should pay close attention to the first-line treatment, improve the cure rate and reduce the death rate (Xinhua News Agency) The novel coronavirus pneumonia clinic in Hubei province held a news conference on 13 evening The director of the Wuhan golden Yin hospital, Zhang Ding Yu, said that there were a lot of comprehensive antibodies against the virus in the patients, and the patients were urged to give plasma after positive treatment (China News Agency) Novel coronavirus pneumonia was adopted by China in Hubei province to adopt the results of clinical diagnosis, which is believed to help patients get clinical care faster The number of confirmed cases increased from the 13 day of the WHO (Xinhua News Agency) In order to implement novel coronavirus pneumonia epidemic prevention and control decisions and deployment by the CPC Central Committee and the State Council, according to the relevant requirements, the State Administration of drug administration has organized supervision and inspection of the quality control of epidemic prevention and control in Beijing, Hebei, Jiangsu and Henan provinces, and urged enterprises to drop the responsibility of substantial management, ensuring the quality, safety and timely supply of medicines (SFDA) Novartis chief executive vas Narasimhan recently reported that investors are moving towards the goal of integrating its manufacturing business into a more focused high-end technology The latest development is that the company plans to stop the Grimsby business in the UK, one of the three main manufacturing plants of Novartis, whose production team has a high reputation within the company (Sina Medical News) On November 11, Ping An Hao released its annual performance report for 2019 The data presented in this performance conference, which moved from offline to online, is really eye-catching From the perspective of financial report, in 2019, the total revenue of Ping an good doctor was 5.065 billion yuan, up 51.8% year-on-year, of which the online medical contribution revenue of core business was 858 million yuan, up 109% year-on-year, and the net loss continued to narrow to 746 million yuan, down 18% year-on-year (shell Society) Today, the FDA issued a drug safety notice, requiring Weicai to automatically withdraw its weight-loss drugs belviq and belviq XR FDA analyzed a 12000 person cardiovascular safety clinical trial called camellia-timi 61, and found that although belviq did not increase cardiovascular risk, it would increase the risk of tumor incidence, with an average of one tumor per 470 people per year Major new tumors include pancreatic cancer, colorectal cancer, and lung cancer Today, Weicai stock fell 1% (source of us and Chinese Medicine) Today, Bristol Myers Squibb announced that the U.S FDA has accepted the biological product license application (BLA) of its car-t therapy targeting CD19 antigen, lisocabatagene maraleucel, to treat adult patients with relapsed / refractory (R / R) large B-cell lymphoma (lbcl), including patients with diffuse large B-cell lymphoma (DLBCL), who have received at least two types of pre-treatment (yaomingkant) Today, Xinda biological class 1 new drug ibi112 was registered by CDE with the acceptance number of cxsl2000021 No specific introduction was found in the previously disclosed prospectus of ibi112 At present, the specific information of the drug is not available (Insight database) On April 14, the marketing application of new drug zl-2401 (omadacycline toluene sulfonate) was undertaken by CDE for acute bacterial skin and skin structural infection This time, two dosage forms including tablet and injection were listed (Insight database) On March 13, the Valsartan hydrochlorothiazide tablets (cyhs1800102) declared by Baiao pharmaceutical industry according to the new 4 categories were approved by the State Food and Drug Administration for listing, which was deemed to have passed the consistency evaluation, and the State Food and drug administration has arranged to issue the drug approval documents This is another large-scale antihypertensive drug obtained by Baiao pharmaceutical industry after the approval of valsartan amlodipine tablets, the first imitation of valsartan tablets, on February 5 (medicine cube) The company's products, Cefalexin Capsules (0.25g and 0.125g), passed the quality and efficacy evaluation of generic drugs, Xinhua Pharmaceutical announced Thursday Up to now, Xinhua Pharmaceutical has invested about 9 million yuan in R & D for the consistency evaluation of the product (Sina Medical News) Today, Seattle genetics announced that the FDA has accepted its new drug application (NDA) for the treatment of unresectable locally advanced or metastatic HER2 positive breast cancer with trastuzumab and capecitabine (yaomingkant)